{"links":{"feed":"https://www.erudio.com/reports/cevolution-nct07555938/feed.json","html":"https://www.erudio.com/reports/cevolution-nct07555938","json":"https://www.erudio.com/reports/cevolution-nct07555938.json","markdown":"https://www.erudio.com/reports/cevolution-nct07555938.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"cevolution-nct07555938"}},"request":"https://www.erudio.com/contact?report=cevolution-nct07555938"},"offer":{"cited_clinicians":1,"cited_commentary_sources":1,"verified_hcp_statements":8,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":1},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=cevolution-nct07555938","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=cevolution-nct07555938","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/cevolution-nct07555938","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 8 verified statements · 8 from 1 confirmed clinician","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-09T21:54:47.787931Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":5,"no_commentary_found":3},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":1,"title":"Potential sequencing after BCMA- or GPRC5D-targeted therapy"}],"counts":{"beyond_population_findings":1,"cited_clinicians":1,"cited_clinicians_by_role":{"physician, Hematology":1},"cited_physicians":1,"cited_sources":1,"claims_by_expression_type":{"comparison":1,"interpretation":2,"opinion":1,"restatement":4},"claims_by_kind":{"source_observation":8},"clinician_statements":8,"evidence_units":1,"findings":1,"people_cited":1,"people_identity_verified":1,"people_total":1,"screened_sources":9,"verified_claims":8},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"One speaker links CEVOLUTION to higher responses with pomalidomide while emphasizing prior-treatment exclusions"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One speaker links combination activity to CEVOLUTION while emphasizing eligibility limits"},{"id":"section-2","level":2,"title":"Beyond the trial population"},{"id":"section-3","level":3,"title":"One speaker envisages a later role but qualifies it with a post-BCMA-bispecific response concern"},{"id":"section-4","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-09T21:54:47.787931Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-09T22:04:43Z","record_hash":"b18cdf356b8bff58443350f807f344e18ad789fecd14eb0ec25e7067ad44c00b","release_hash":"bbb1957b65037cb8f85c34a8dfa0585f79c53d2abba5c2a1c63615d79500926b","report_id":"erudio-nct07555938","run_id":"28fe3d95-cf34-48ec-8fa4-938b080e0a86","schema_version":"5.0","slug":"cevolution-nct07555938","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A hematologist described in the sources as involved in CEVOLUTION cites higher activity with pomalidomide as a rationale for testing the combination, not randomized evidence of benefit. In broader sequencing commentary, they envisage use after BCMA- or GPRC5D-targeted therapy beyond what the trial can address, while noting lower monotherapy responses specifically after a BCMA bispecific. Comparative benefit and safety cannot be judged from the discussion.","examples":[],"meta_description":"9 sources screened · 8 verified statements (8 from clinicians verified by NPI or staff page) from 1 source · 1 finding. Updated Nov 9, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-09T22:04:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":9},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 86 sources about other trials or topics are not included.","The substantive views come from one interview with a speaker described in the source as involved in CEVOLUTION; they cannot establish broader clinician agreement or disagreement.","Public discussion was not exhaustively covered, so unnamed trial references and alternative transcriptions may be missing.","The supporting cohort sizes, follow-up and response definitions are not given, and MRD negativity is not quantified; the cited response figures cannot be treated as controlled comparative estimates.","The interview does not discuss randomized CEVOLUTION outcomes or safety and tolerability, limiting any benefit-risk interpretation.","No publication for this exact trial was found, and no protocol was listed in the registry material reviewed; a fuller assessment of methods and corroboration of the interview's statements was therefore unavailable."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":0,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":1},"count":1,"evidence_window":{"end":"2026-09-29","start":"2026-09-29"},"retrieval_snapshot":"2026-11-09T21:42:26.114784Z","timeline":[{"count":1,"week":"2026-W40"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07555938:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07555938:context","quote_policy":"short_quote_link_out"},{"id":"openfda:3c222961-5398-4185-b2d0-defe90230094:20260901","quote_policy":"short_quote_link_out"},{"id":"openfda:11f10a47-1c42-40e4-89d8-bb000fef497c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3msiv4bbnoc2w","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080241531567399279:0dde8ef8-76cf-4a5f-b0eb-36855fb19df6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082059015463305520:cdddf7d9-48af-404b-ac5e-2df27d55ecde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085751748094754910:5bfb30e5-0350-4741-9686-2a3d7f79ca1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096301683748077595:f85d5baf-8945-448e-8d8d-7d637cfdb513","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103128227229155354:506726c1-c1fe-497f-afa5-ed1ebea6ed06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103128996321845267:5225eb4c-97b5-486f-82e1-5cdcbb8f73aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108683594277454037:ac92adf3-2024-42b9-a3f9-824947f1801a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:w9_xDAgdtl8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-10-09","start":"2026-07-23"},"retrieval_snapshot":"2026-11-09T21:42:26.114784Z","timeline":[{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":2,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":0,"x_video":0,"youtube":8}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: cevostamab","status":"unmapped"},{"brand_names":["Pomalyst"],"label":"pomalidomide","slug":"pomalidomide"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"reason":"Unmapped registry intervention: elotuzumab","status":"unmapped"},{"brand_names":["Kyprolis"],"label":"carfilzomib","slug":"carfilzomib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"CEVOLUTION","aliases":["CEVOLUTION","Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy"],"brief_title":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"display_condition":"previously treated multiple myeloma","display_interventions":[["cevostamab"]],"enrollment":{"count":380,"type":"ESTIMATED"},"interventions":[{"name":"Cevostamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pomalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Elotuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carfilzomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07555938","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate","timeFrame":"Up to 1 year after the last participant is randomized"},{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 5 years after the last participant is randomized"}],"registered_date":{"date":"2026-04-29","type":"ACTUAL"},"registry_last_updated":"2026-10-13","registry_url":"https://clinicaltrials.gov/study/NCT07555938","short_name":"CEVOLUTION","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2026-06-23","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CO46096","type":"sponsor_study_id"},{"id":"2025-524028-23-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}